Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899644 | 0.77 | ERN1 (0.55) | ERN1CDK1TRIM24TRIM33 | |
| SCHEMBL2914126 | 0.75 | TP53 (0.42) | — | |
| SCHEMBL6094668 | 0.74 | ERN1 (0.57) | ERN1CDK1TRIM24TRIM33 | |
| SCHEMBL2641952 | 0.74 | ERN1 (0.52) | ERN1CDK1TRIM24TRIM33 | |
| SCHEMBL10645203 | 0.73 | ERN1 (0.51) | ERN1 | |
| SCHEMBL79298 | 0.73 | ERN1 (1.00) | ERN1 | |
| SCHEMBL30135697 | 0.73 | ERN1 (1.00) | ERN1 | |
| SCHEMBL11165076 | 0.72 | MCL1 (0.59) | — | |
| SCHEMBL11417323 | 0.71 | ERN1 (0.96) | ERN1 | |
| SCHEMBL3902703 | 0.71 | NR1H2 (0.52) | ERN1CDK1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59122577-A | — | — | None | — | — | JP | disclosed |
| JP-60054388-A | — | — | None | — | — | JP | disclosed |
| JP-60177089-A | — | — | None | — | — | JP | disclosed |
| JP-4297480-A | — | — | None | — | — | JP | disclosed |
| EP-1569645-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569942-A2 | TRICYCLIC AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569938-A1 | METHOD OF MAKING TRICYCLIC AMINOCYANOPYRIDINE COMPOUNDS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6909001-B2 | Method of making tricyclic aminocyanopyridine compounds | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040127511-A1 | Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-0411157-A1 | SPIROPYRAN COMPOUNDS | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1991-02-06 | — | — | EP | disclosed |
| US-4753867-A | INDOLINOSPIROBENZOTHIOPYRAN COMPOUND | SONY CORPORATION (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0115201-B1 | PHOTOSENSITIVE COMPOSITIONS CONTAINING PHOTOCHROMIC COMPOUNDS | SONY CORPORATION (JP) | 1988-03-02 | — | — | EP | disclosed |
| EP-0189188-A2 | Optical recording medium | SONY CORPORATION (JP) | 1986-07-30 | — | — | EP | disclosed |
| US-4565779-A | Photochromic compounds and photosensitive compositions containing the compounds | SONY CORPORATION (JP) | 1986-01-21 | — | — | US | disclosed |
| JP-S60177089-A | PHOTOCHROMIC COMPOUND | SONY CORP | 1985-09-11 | — | — | JP | disclosed |
| JP-S6054388-A | PHOTOCHROMIC COMPOUND | SONY CORP | 1985-03-28 | — | — | JP | disclosed |
| EP-0115201-A2 | Photosensitive compositions containing photochromic compounds | SONY CORPORATION (JP) | 1984-08-08 | — | — | EP | disclosed |
| JP-S59122577-A | PHOTOCHROMIC COMPOSITION | SONY CORP | 1984-07-16 | — | — | JP | disclosed |
| JP-S0654388-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP2K2, MAP3K2 | ERN1 1456/4885CDK1 268/4885ALDH5A1 3178/4885 |
| US-20040127511-A1 | Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | MAPKAPK2, MAP4K2, MAP3K2 | ERN1 1639/4885CDK1 104/4885ALDH5A1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.